A Phase 2 Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1

[1] A Phase 2 Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin?) Compared to Sunitinib (Sutent?) in Participants With Untreated Advanced Renal Cell Carcinoma (IMmotion150) NCT01984242
[2] Atkins MB, McDermott DF, Powles T, Motzer RJ, Rini BI, Fong L, Joseph RW, et all. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). J Clin Oncol 35, 2017 (suppl; abstr 4505)
[3] A Randomized Phase 3 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy – (OAK Trial) – NCT02008227
[4] Gandara DR, Von Pawel J, Sullivan RN, Helland A, Han JY, Aix SP, Rittmeyer A, et all. Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study. J Clin Oncol 35, 2017 (suppl; abstr 9001)
[5] A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors – NCT01633970
[6] Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi SF, Ready NE, et all. Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study. J Clin Oncol 35, 2017 (suppl; abstr 9092)
[7] Sullivan RJ, Gonzalez R, Lewis KD, Hamid O, Infante JR, Patel MR, Hodi FS, et all. Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity. J Clin Oncol 35, 2017 (suppl; abstr 3063)
[8] A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma – NCT01656642
[9] Miller WH, Kim TM, Lee CB, Flaherty KT, Reddy S, Jamal R, Chow LQ, Rooney IA, et all. Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. J Clin Oncol 35, 2017 (suppl; abstr 3057)
[10] Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors – NCT01988896